Merck warns doctors to stop prescribing Tredaptive

by The Associated Press

Drugmaker Merck says it is suspending its sale of the cholesterol drug Tredaptive and is telling doctors to quit prescribing the medicine.

Tredaptive is available in about 70 countries, including Europe. The drug is not approved in the United States.

Merck last month said initial results from a late-stage study showed that adding Tredaptive to traditional did not lower the risk of heart attack, stroke and related problems.

Results also showed that patients taking the cholesterol were more likely to suffer some serious, non-fatal adverse events.

Merck says it made its decision based in part on a European Medicine Agency committee recommendation.

Merck has advised patients to quit taking the drug only after talking to a physician.

1 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Merck says cholesterol drug failed to show benefit

Dec 20, 2012

Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.

FDA backs Vytorin for kidney disease patients

Oct 31, 2011

(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.

FDA to review Vytorin results

Jan 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

11 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments